Odyssean LLC Boosts Stake in Adaptive Biotechnologies Corporation $ADPT

Odyssean LLC raised its holdings in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 320.1% during the second quarter, Holdings Channel.com reports. The firm owned 67,709 shares of the company’s stock after purchasing an additional 51,592 shares during the period. Odyssean LLC’s holdings in Adaptive Biotechnologies were worth $1,452,000 at the end of the most recent quarter.

Several other large investors have also modified their holdings of ADPT. BlackRock Inc. acquired a new stake in shares of Adaptive Biotechnologies during the 2nd quarter worth about $324,735,000. Westfield Capital Management Co. LP acquired a new position in Adaptive Biotechnologies in the fourth quarter valued at about $65,942,000. Price T Rowe Associates Inc. MD boosted its stake in Adaptive Biotechnologies by 303.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after buying an additional 3,299,635 shares during the period. Ameriprise Financial Inc. boosted its stake in Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after buying an additional 2,731,648 shares during the period. Finally, Invesco Ltd. boosted its stake in Adaptive Biotechnologies by 248.8% during the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock worth $50,468,000 after buying an additional 2,216,595 shares during the period. Institutional investors and hedge funds own 99.17% of the company’s stock.

Adaptive Biotechnologies Price Performance

Shares of ADPT opened at $24.28 on Friday. The company has a market cap of $3.87 billion, a P/E ratio of -59.22 and a beta of 2.09. Adaptive Biotechnologies Corporation has a fifty-two week low of $12.00 and a fifty-two week high of $26.87. The company has a quick ratio of 4.68, a current ratio of 4.79 and a debt-to-equity ratio of 2.22. The firm’s 50 day moving average price is $23.47 and its 200 day moving average price is $17.96.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The business had revenue of $71.55 million during the quarter, compared to analysts’ expectations of $65.44 million. Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The business’s quarterly revenue was up 21.5% on a year-over-year basis. During the same period in the prior year, the business earned ($0.17) EPS. On average, research analysts forecast that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ADPT. Piper Sandler boosted their price target on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Morgan Stanley increased their price objective on shares of Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 30th. Guggenheim lifted their target price on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. Finally, TD Cowen boosted their price objective on Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Adaptive Biotechnologies currently has an average rating of “Moderate Buy” and a consensus target price of $24.42.

Insiders Place Their Bets

In other Adaptive Biotechnologies news, CEO Chad Robins sold 278,676 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $24.48, for a total transaction of $6,821,988.48. Following the completion of the transaction, the chief executive officer owned 2,180,518 shares in the company, valued at $53,379,080.64. The trade was a 11.33% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Robert Hershberg sold 30,664 shares of the business’s stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $24.40, for a total transaction of $748,201.60. Following the transaction, the director owned 46,683 shares of the company’s stock, valued at approximately $1,139,065.20. The trade was a 39.64% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 2,011,584 shares of company stock valued at $45,765,999. 5.70% of the stock is owned by company insiders.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.